Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: a Review

Purpose There is a growing interest in continuous biopharmaceutical processing due to the advantages of small footprint, increased productivity, consistent product quality, high process flexibility and robustness, facility cost-effectiveness, and reduced capital and operating cost. To support the decision making of biopharmaceutical manufacturing, comparisons between conventional batch and continuous processing are provided. Methods Various process unit operations in different operating modes are summarized. Software implementation as well as computational methods used are analyzed pointing to the advantages and disadvantages that have been highlighted in the literature. Economic analysis methods and their applications in different parts of the processes are also discussed with examples from publications in the last decade. Results The results of the comparison between batch and continuous process operation alternatives are discussed. Possible improvements in process design and analysis are recommended. The methods used here do not reflect Lilly’s cost structures or economic evaluation methods. Conclusion This paper provides a review of the work that has been published in the literature on computational process design and economic analysis methods on continuous biopharmaceutical antibody production and its comparison with a conventional batch process.

[1]  Kurt Brorson,et al.  The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing. , 2019, Trends in biotechnology.

[2]  José González-Valdez,et al.  Novel Aspects and Future Trends in The Use of Aqueous Two-Phase System as a Bioengineering Tool , 2018 .

[3]  Ana M Azevedo,et al.  Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. , 2009, Trends in biotechnology.

[4]  Suzanne S. Farid,et al.  Economic Drivers and Trade-Offs in Antibody Purification Processes : The future of therapeutic MAbs lies in the development of economically feasible downstream processes , 2008 .

[5]  William G. Whitford,et al.  Single‐Use Systems Support Continuous Bioprocessing by Perfusion Culture , 2014 .

[7]  Hemanthram Varadaraju,et al.  Process and economic evaluation for monoclonal antibody purification using a membrane‐only process , 2011, Biotechnology progress.

[8]  Marco Rito-Palomares,et al.  Continuous aqueous two-phase systems devices for the recovery of biological products , 2014 .

[9]  Gavin Towler,et al.  Chemical engineering design : principles, practice, and economics of plant and process design , 2008 .

[10]  Rene Gantier,et al.  A straightforward methodology for designing continuous monoclonal antibody capture multi-column chromatography processes. , 2015, Journal of chromatography. A.

[11]  Jonathan P. Raftery,et al.  Economic improvement of continuous pharmaceutical production via the optimal control of a multifeed bioreactor , 2017, Biotechnology progress.

[12]  Suzanne S Farid,et al.  Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture , 2017, Biotechnology progress.

[13]  B. Ogunnaike,et al.  Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation , 2017, Antibodies.

[14]  Suzanne S Farid,et al.  Established bioprocesses for producing antibodies as a basis for future planning. , 2006, Advances in biochemical engineering/biotechnology.

[15]  W. Shrank,et al.  Pricing of monoclonal antibody therapies: higher if used for cancer? , 2018, The American journal of managed care.

[16]  Paola Lettieri,et al.  Life‐cycle and cost of goods assessment of fed‐batch and perfusion‐based manufacturing processes for mAbs , 2016, Biotechnology progress.

[17]  Uwe Gottschalk,et al.  Single-use disposable technologies for biopharmaceutical manufacturing. , 2013, Trends in biotechnology.

[18]  Jochen Strube,et al.  Trends in Upstream and Downstream Process Development for Antibody Manufacturing. , 2014, Bioengineering.

[19]  Eva Sorensen,et al.  Design of high productivity sequential multi-column chromatography for antibody capture , 2014 .

[20]  Fernando L. Taracena An Economic Analysis for Product and Process Design , 2006 .

[21]  Rashmi Kshirsagar,et al.  Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity. , 2016, Journal of biotechnology.

[22]  John Ahmet Erkoyuncu,et al.  Discrete Event Simulation Modelling for Dynamic Decision Making in Biopharmaceutical Manufacturing , 2016 .

[23]  James Hayes,et al.  Identifying a robust design space for glycosylation during monoclonal antibody production , 2016, Biotechnology progress.

[25]  Andrew D. Tustian,et al.  Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography. , 2015, Journal of biotechnology.

[26]  Massimo Morbidelli,et al.  Twin-column CaptureSMB: a novel cyclic process for protein A affinity chromatography. , 2015, Journal of chromatography. A.

[27]  Michael C. Flickinger,et al.  Upstream industrial biotechnology , 2013 .

[28]  Adriana G. Lopes,et al.  Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitations , 2015 .

[29]  G. Schembecker,et al.  Continuous viral inactivation at low pH value in antibody manufacturing , 2016 .

[30]  N J Titchener-Hooker,et al.  Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. , 2001, Biotechnology and bioengineering.

[31]  P. Ashouri,et al.  A dynamic simulation framework for biopharmaceutical capacity management , 2011 .

[32]  Konstantin Konstantinov,et al.  End-to-end integrated fully continuous production of recombinant monoclonal antibodies. , 2015, Journal of biotechnology.

[33]  I. Apostol,et al.  Monoclonal antibody disulfide reduction during manufacturing , 2013, mAbs.

[34]  Andrew L. Zydney,et al.  Continuous Countercurrent Tangential Chromatography for Monoclonal Antibody Purification , 2013 .

[35]  Masahiko Hirao,et al.  Erratum to: Decision-Support Method for the Choice Between Single-Use and Multi-Use Technologies in Sterile Drug Product Manufacturing , 2017, Journal of Pharmaceutical Innovation.

[36]  Kristina Pleitt,et al.  Progression of continuous downstream processing of monoclonal antibodies: Current trends and challenges , 2018, Biotechnology and bioengineering.

[37]  Gerhard Schembecker,et al.  Cost evaluation of antibody production processes in different operation modes , 2016 .

[38]  Mario A Torres-Acosta,et al.  Economic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two‐phase extraction (with and without PEG recycle) , 2015, Biotechnology progress.

[39]  Sen Xu,et al.  Bioreactor productivity and media cost comparison for different intensified cell culture processes , 2017, Biotechnology progress.

[40]  Lazaros G. Papageorgiou,et al.  Integrated Optimization of Upstream and Downstream Processing in Biopharmaceutical Manufacturing under Uncertainty: A Chance Constrained Programming Approach , 2016 .

[41]  José González-Valdez,et al.  Aqueous Two‐Phase Systems at Large Scale: Challenges and Opportunities , 2018, Biotechnology journal.

[42]  Massimo Morbidelli,et al.  Continuous counter‐current chromatography for capture and polishing steps in biopharmaceutical production , 2016, Biotechnology journal.

[43]  L. Castilho Continuous Animal Cell Perfusion Processes: The First Step Toward Integrated Continuous Biomanufacturing , 2014 .

[44]  Eric S. Langer,et al.  Single‐use technologies in biopharmaceutical manufacturing: A 10‐year review of trends and the future , 2014 .

[45]  Alois Jungbauer,et al.  Economics of recombinant antibody production processes at various scales: Industry-standard compared to continuous precipitation. , 2014, Biotechnology journal.

[46]  Anirudh M. K. Nambiar,et al.  Countercurrent staged diafiltration for formulation of high value proteins , 2018, Biotechnology and bioengineering.

[47]  P. Shamlou,et al.  Design, construction, and optimization of a novel, modular, and scalable incubation chamber for continuous viral inactivation , 2017, Biotechnology progress.

[48]  Mark Pagkaliwangan,et al.  Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales , 2019, Biotechnology journal.

[49]  An integrated practical implementation of continuous aqueous two-phase systems for the recovery of human IgG: From the microdevice to a multistage bench-scale mixer-settler device. , 2016, Biotechnology journal.

[50]  Zheng Jian Li,et al.  Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest , 2017 .

[51]  A. Zydney,et al.  Performance optimization of continuous countercurrent tangential chromatography for antibody capture , 2016, Biotechnology progress.

[52]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[53]  Anurag S Rathore,et al.  Continuous Processing for Production of Biopharmaceuticals , 2015, Preparative biochemistry & biotechnology.

[54]  Daniel G Bracewell,et al.  Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. , 2013, Journal of chromatography. A.

[55]  Satoshi Ohtake,et al.  Cell-Free Synthesis Meets Antibody Production: A Review , 2015 .

[56]  Lindsay Arnold,et al.  Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm , 2019, Biotechnology journal.

[57]  Mario A Torres-Acosta,et al.  Economic evaluation of the primary recovery of tetracycline with traditional and novel aqueous two-phase systems , 2018, Separation and purification technology.

[58]  M. Aires-Barros,et al.  Aqueous two-phase extraction as a platform in the biomanufacturing industry: economical and environmental sustainability. , 2011, Biotechnology advances.

[59]  Marc Bisschops,et al.  platforms Single-Use , Continuous-Countercurrent , Multicolumn Chromatography , 2009 .

[60]  Ana M Azevedo,et al.  Continuous purification of antibodies from cell culture supernatant with aqueous two-phase systems: from concept to process. , 2013, Biotechnology journal.

[61]  M. Schofield,et al.  Transfer of a three step mAb chromatography process from batch to continuous: Optimizing productivity to minimize consumable requirements. , 2017, Journal of biotechnology.

[62]  David S. Kahn,et al.  Continuous countercurrent tangential chromatography for mixed mode post-capture operations in monoclonal antibody purification. , 2017, Journal of chromatography. A.

[63]  Massimo Morbidelli,et al.  Perfusion mammalian cell culture for recombinant protein manufacturing - A critical review. , 2018, Biotechnology advances.

[64]  Songsong Liu,et al.  Designing cost‐effective biopharmaceutical facilities using mixed‐integer optimization , 2013, Biotechnology progress.

[65]  Anurag S. Rathore,et al.  Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. , 2018, Journal of chromatography. A.

[66]  Alois Jungbauer,et al.  Continuous downstream processing of biopharmaceuticals. , 2013, Trends in biotechnology.

[67]  Suzanne S Farid,et al.  Fed‐batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty , 2013, Biotechnology and bioengineering.

[68]  Suzanne S. Farid,et al.  Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures , 2016, Biotechnology journal.

[69]  Suzanne S. Farid,et al.  Evaluating the economic and operational feasibility of continuous processes for monoclonal antibodies , 2014 .

[70]  Konstantin B Konstantinov,et al.  White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. , 2015, Journal of pharmaceutical sciences.

[71]  M Angela Taipa,et al.  Antibodies and Genetically Engineered Related Molecules: Production and Purification , 2004, Biotechnology progress.

[72]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[73]  Suzanne S Farid,et al.  Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[74]  Yao-ming Huang,et al.  Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product quality , 2014, Biotechnology progress.

[75]  Marcos Antonio de Oliveira,et al.  Biopharmaceuticals from microorganisms: from production to purification , 2016, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[76]  S. Dübel,et al.  Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates , 2017, Scientific Reports.

[77]  M. Aires-Barros,et al.  Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals. , 2010, Journal of chromatography. A.

[78]  Joanna Rucker-Pezzini,et al.  Single Pass Diafiltration Integrated into a Fully Continuous mAb Purification Process. , 2018, Biotechnology and bioengineering.

[79]  Demetri Petrides,et al.  Bioprocess Design and Economics , 2003 .

[80]  M. Aires-Barros,et al.  Continuous aqueous two-phase extraction of human antibodies using a packed column. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[81]  Andrew L. Zydney,et al.  Continuous downstream processing for high value biological products: A Review , 2016, Biotechnology and bioengineering.

[82]  Alex Xenopoulos,et al.  A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies. , 2015, Journal of biotechnology.

[83]  Martin Lobedann,et al.  A Biomanufacturing Facility Based On Continuous Processing And Single Use Technology , 2015 .

[84]  A. Spirin,et al.  Continuous-Flow and Continuous-Exchange Cell-Free Translation Systems and Reactors , 2002 .

[85]  Nigel J. Titchener‐Hooker,et al.  Economic analysis of royalactin production under uncertainty: Evaluating the effect of parameter optimization , 2015, Biotechnology progress.

[86]  Michael C Jewett,et al.  Development of a CHO-Based Cell-Free Platform for Synthesis of Active Monoclonal Antibodies. , 2017, ACS synthetic biology.

[87]  Angelo Lucia Chemical Engineering Design Principles, Practice, and Economics of Plant and Process Design By G. Towler and R. Sinnott , 2008 .

[88]  Ye Zhang,et al.  Very High Density of CHO Cells in Perfusion by ATF or TFF in WAVE Bioreactor™. Part I. Effect of the Cell Density on the Process , 2013, Biotechnology progress.

[89]  Daniar Hussain,et al.  Countercurrent tangential chromatography for large‐scale protein purification , 2011, Biotechnology and bioengineering.

[90]  Frank Riske,et al.  Periodic counter-current chromatography -- design and operational considerations for integrated and continuous purification of proteins. , 2012, Biotechnology journal.

[91]  R. Bayer,et al.  Recovery and purification process development for monoclonal antibody production , 2010, mAbs.

[92]  Lazaros G. Papageorgiou,et al.  Multi-objective optimisation for biopharmaceutical manufacturing under uncertainty , 2018, Comput. Chem. Eng..

[93]  Massimo Morbidelli,et al.  Characterization and comparison of ATF and TFF in stirred bioreactors for continuous mammalian cell culture processes , 2016 .

[94]  Jason Walther,et al.  The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. , 2015, Journal of biotechnology.

[95]  M. Hurme,et al.  Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes , 2011, Biotechnology progress.

[96]  Jochen Strube,et al.  Integration of Aqueous Two-Phase Extraction as Cell Harvest and Capture Operation in the Manufacturing Process of Monoclonal Antibodies , 2017, Antibodies.

[97]  Marco Rito-Palomares,et al.  Process Economics: Evaluation of the Potential of ATPS as a Feasible Alternative to Traditional Fractionation Techniques , 2017 .

[98]  Jochen Strube,et al.  Multi‐Stage Aqueous Two‐Phase Extraction for the Purification of Monoclonal Antibodies , 2014 .

[99]  Karan Sukhija,et al.  A Single-use Strategy to Enable Manufacturing of Affordable Biologics , 2016, Computational and structural biotechnology journal.

[100]  Ashok Kumar,et al.  Upstream processes in antibody production: evaluation of critical parameters. , 2008, Biotechnology advances.

[101]  Lawrence X. Yu,et al.  Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality. , 2016, International journal of pharmaceutics.

[102]  Anurag S. Rathore,et al.  Process integration and control in continuous bioprocessing , 2018, Current Opinion in Chemical Engineering.

[103]  Rohan Patil,et al.  Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies. , 2018, Advances in biochemical engineering/biotechnology.

[104]  Ana M Azevedo,et al.  Monoclonal Antibodies Production Platforms: An Opportunity Study of a Non-Protein-A Chromatographic Platform Based on Process Economics. , 2017, Biotechnology journal.

[105]  Charles L. Cooney,et al.  White Paper on Continuous Bioprocessing , 2014 .

[106]  Daniel G. Bracewell,et al.  Cell free protein synthesis: a viable option for stratified medicines manufacturing? , 2017 .